IP Library Granted Patent US 7,998,739
Granted Patent B2
US 7,998,739 · App. 11/218,906 · Granted Aug 16, 2011

Methods of activating NKT cells

Assignees: The Scipps Research Institute; Brigham Young University; The University of Chicago
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,998,739
App. No.
11/218,906
Granted
Aug 16, 2011
Kind
B2
Abstract

Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the NKT cell. Methods of activating an NKT cell population in a subject are also provided.

Claims (12)

1. A method of activating an NKT cell comprising contacting the NKT cell in vitro with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell or upregulate expression of a cell surface marker on the NKT cell, wherein the iGb3 is presented to the NKT cell in complex with cell-free, recombinant CD1d that is multivalent.

2. The method of claim 1 , wherein the iGb3 is purified.

3. The method of claim 1 , wherein the iGb3 is synthetic.

4. The method of claim 1 , wherein contacting the NKT cell comprises contacting a T cell receptor of the NKT cell.

5. The method of claim 1 , wherein the NKT cell is cultured in vitro.

6. The method of claim 1 , wherein the cytokine is selected from the group consisting of IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, TNF-α, TNF-β, IFN-γ and combinations thereof.

7. The method of claim 6 , wherein the cytokine is IFN-γ.

8. The method of claim 6 , wherein the cytokine is IL-2.

9. The method of claim 6 , wherein the cytokine is IL-4.

10. The method of claim 1 , wherein the cell surface marker is an IL-12 receptor or CD40L.

11. A method of inducing secretion of a cytokine from an NKT cell comprising contacting the NKT cell in vitro with iGb3, wherein the iGb3 is presented to the NKT cells in complex with cell-free, recombinant CD1d that is multivalent.

12. A method of upregulating expression of a cell surface marker on an NKT cell comprising contacting the NKT cell in vitro with iGb3, wherein the iGb3 is presented to the NKT cell in complex with cell-free, recombinant CD1d that is multivalent.

Assignments (4)
CONFIRMATORY LICENSE Recorded Dec 21, 2017
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044935/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2005
From: BENDELAC, ALBERT; ZHOU, DAPENG
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 016877/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2005
From: TEYTON, LUC
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 016877/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2005
From: SAVAGE, PAUL
To: BRIGHAM YOUNG UNIVERSITY
Reel/Frame 016877/0507 →
Continuity (2)
Provisional Application 60606941 · Sep 3, 2004
Related Publication 20060073118A1 · Apr 6, 2006